Enlivex Therapeutics expects cash to fund operations through end of 2025

As of June 30, 2023, Enlivex had cash and cash equivalents, short term bank deposits and long term interest-bearing bank deposits of approximately $36 million. The Company believes its existing cash and cash equivalents will be sufficient to fund its operating expenses and capital expenditure requirements through the end of 2025.